TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05627739
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Glucocorticoid is started at a dose of 0.5-0.8 mg/kg/day, and 60 mg daily was the highest dose. Mycophenolate mofetilwas is started at a dose of 0.5-1.0g bid.
Study: NCT04816253
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediately after removal of impacted tooth (hyaluronic acid) placed in extraction socket
Study: NCT04816253
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednsolone will be injected half an hour preoperatively
Study: NCT05017480
Drug: CBP-201
Normalized name: CBPC
DrugBank: Carbenicillin (DB00578)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CBP-201 subcutaneous(SC) injection.
Study: NCT05905120
Drug: Toludivenlafaxine hydrochloride sustained-release tablets
Normalized name: bupropion
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg/tablet, 2 tablets each time, once a day, for 4 days, orally at 30 min after the start of meals, 200 mL water to take
Study: NCT05823675
Drug: Itolizumab
Normalized name: Itolizumab
DrugBank: Itolizumab (DB16207)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive Itolizumab concomitant within 72 hours of systematic Corticosteroids.
Study: NCT05823675
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone will be taperred as required
Study: NCT05290155
Drug: anti-CD7 CAR-T cells
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration with anti-CD7 CAR-T cells in the relapsed/refractory T cell hematological malignancy patients
Study: NCT06279286
Drug: HS-10506
Normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HS-10506, tablets (10mg, 20mg, 40mg and 80mg) at night once daily from Day 1 to Day 5 in phase Ib study, and from Day 1 to Day 28 in phase II study.
Study: NCT05920889
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.5mg subcutaneous injection of the drug before or during EVT, and 7 days after the procedure. i.e. patient will receive a total of 2 injections.
Study: NCT05246293
Drug: Tofacitinib
Normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tofacitinib in doses of 5 mg BID, in RA-ILD patients at stable doses of prednisone ≤ 10 mg/day during the last three months.~Patients who met the inclusion criteria of the study protocol will received tofacitinib 5 mg BID for 12 months
Study: NCT05502250
Drug: gemcitabine, cisplatin and tislelizumab
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients will receive 2 cycles of gemcitabine and cisplatin (GP) + tislelizumab. Each cycle lasts 21 days. Treatment is given through an IV line on day 1 and 8.~After 2 cycles a FDG-PET-CT scan will be performed. Patients who respond well will proceed with 2 additional cycles of GP + tislelizumab . Patients with insufficient response will stop with the study treatment and they will continue treatment according to local practice.~After 4 cycles of GP + tislelizumab another FDG-PET-CT scan will be performed. If this scan shows that the disease is under control (metabolic complete remission) patients will proceed with 13 cycles of tislelizumab consolidation treatment (21 day cycles). Treatment is given on day 1 through an IV line.
Study: NCT06099379
Drug: ∆9-tetrahydrocannabinol
DrugBank: Cannabinol (DB14737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytocannabinoids from plant inflorescences (CBD and THC dominant) - inhaled
Study: NCT06407297
Drug: UCMSCs
Normalized name: HUCMSCs
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral intravenous infusion of umbilical cord mesenchymal stem cells
Study: NCT05038657
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment will consist of atezolizumab, by IV infusion, at a fixed dose of 1680 mg, every 28 days (day 1 of each cycle, +/- 3 days), for up to one year. Each participant will receive up to 13 doses in total.
Study: NCT05151588
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75mg/m2 intravenous infusion on day 1 every 3 weeks for 3 cycles as induction therapy
Study: NCT05151588
Drug: Cis Platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 75mg/m2 intravenous infusion on day 1 every 3 weeks for 3 cycles as induction therapy
Study: NCT05151588
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU 750mg/m2 intravenous infusion from day 1 to day 5 every 3 weeks for 3 cycles as induction therapy
Study: NCT05151588
Drug: Tazemetostat
Normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tazemetostat 800mg twice per day orally in continuously for 3 cycles as induction therapy and maintenance therapy
Study: NCT05096663
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally (PO)
Study: NCT05096663
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT05096663
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05096663
Drug: Nogapendekin Alfa
Normalized name: Nogapendekin alfa
DrugBank: Nogapendekin alfa (DB18740)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given SC
Study: NCT05096663
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT05913661
Drug: Pemigatinib
Normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pemigatinib is scheduled to be administered at a dose of 13.5 mg quaque die according to a 2-week dosing and 1-week discontinuation regimen.
Study: NCT05913661
Drug: PD-1 Inhibitors
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dosing regimen is 200 mg IV Q3W
Study: NCT05598593
Drug: cytarabine+thiotepa+ fludarabine + busulfan
Normalized name: Busulfan
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cytarabine+thiotepa+ fludarabine + busulfan intravenous injection
Study: NCT06246565
Drug: HS-10383
Normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HS-10383 administered as one 50 mg, 100 mg 200 mg tablet once daily, depending upon randomization.
Study: NCT06490913
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 130mg/m2, ivgtt, d1，q3w，1cycle
Study: NCT06490913
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: cetuximab 500mg/m2, q2w
Study: NCT06490913
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 85mg/m2, d1,q2w
Study: NCT06490913
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400mg/m2，d1,q2w
Study: NCT05333809
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: an anti-PD-1 monoclonal antibody
Study: NCT05333809
Drug: Disitamab vedotin
Normalized name: Disitamab vedotin
DrugBank: Disitamab vedotin (DB17208)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HER2-ADC
Study: NCT06215976
Drug: Metformin Hydrochloride 500 MG
Normalized name: metformin hydrochloride 500 MG
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 500mg tablets twice daily
Study: NCT05169515
Drug: SC Mosunetuzumab
Normalized name: Mosunetuzumab
DrugBank: Mosunetuzumab (DB15434)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive SC mosunetuzumab for 12 cycles (cycle length = 21 days or 28 days for Cycle 1 and 28 days for Cycles 2-12)
Study: NCT05169515
Drug: IV Glofitamab
Normalized name: Glofitamab
DrugBank: Glofitamab (DB16371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive IV glofitamab for 12 cycles (cycle length = 21 days)
Study: NCT05169515
Drug: Iberdomide
Normalized name: Iberdomide
DrugBank: Iberdomide (DB12101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 1: Participants will receive oral CC-220 from Day 1-21 of Cycle 2-12 (cycle length = 28 days for Cycles 2-12)
Study: NCT06022237
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 - 1000 IU daily
Study: NCT05506007
Drug: DA-5216
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the cross-over \[Part A\], patients will be randomly assigned to receive one of the following treatment sequences:~* Sequence I. Single dose of DA-5216-R(Fasting) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8.~* Sequence II. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216-R(Fasting) on Day 8.
Study: NCT05506007
Drug: DA-5216
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the cross-over \[Part B\], patients will be randomly assigned to receive one of the following treatment sequences:~* Sequence I. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216(Fed) on Day 8.~* Sequence II. Single dose of DA-5216(Fed) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8.
Study: NCT04865653
Drug: Lysergic Acid Diethylamide Base oral drinking solution
Normalized name: Lysergic acid diethylamide
DrugBank: Lysergic acid diethylamide (DB04829)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A moderate dose of 0.1 mg LSD will be administered.
Study: NCT04865653
Drug: Lysergic Acid Diethylamide Base solid orodispersible film
Normalized name: Lysergic acid diethylamide
DrugBank: Lysergic acid diethylamide (DB04829)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A moderate dose of 0.1 mg LSD will be administered.
Study: NCT04865653
Drug: Lysergic Acid Diethylamide Tartrate oral drinking solution
Normalized name: tartrate
DrugBank: Lysergic acid diethylamide (DB04829)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A moderate dose of 0.146 mg LSD tartrate will be administered (equivalent to 0.1 mg LSD base).
Study: NCT04865653
Drug: Lysergic Acid Diethylamide Tartrate intravenous administration
Normalized name: tartrate
DrugBank: Lysergic acid diethylamide (DB04829)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A moderate dose of 0.146 mg LSD tartrate will be administered (equivalent to 0.1 mg LSD base).
Study: NCT05169515
Drug: Golcadomide
Normalized name: Golcadomide
DrugBank: Golcadomide (DB18115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 1: Participants will receive oral golcadomide from Day 1-14 starting in either Cycle 1 or Cycle 2 through Cycle 12 (cycle length = 28 days for cycles when golcadomide is to be administered) Arm 2: Participants will receive oral golcadomide from Day 1-10 starting in either Cycle 1, Cycle 2 or Cycle 3 through Cycle 12 (cycle length = 21 days)
Study: NCT05169515
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants in Arm 2 will receive pre-treatment with IV obinutuzumab on Cycle 1 Day 1 (cycle length = 21 days)
Study: NCT05169515
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS)
Study: NCT06035354
Drug: AK120
Normalized name: Abiraterone acetate
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: subcutaneous injection once a week
Study: NCT06035354
Drug: AK120
Normalized name: Abiraterone acetate
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: subcutaneous injection every 2 weeks.
Study: NCT06265675
Drug: Celestone
Normalized name: Celestone
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemical neurolysis with corticosteroid
Study: NCT06265675
Drug: Lidocain
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemical neurolysis with local anesthetic
Study: NCT05723770
Drug: instillation of NOV03
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This trial consists of 2 office visits over a period of approximately 2 weeks. At Visit 2, a designated clinical staff member or the investigator will instill 1 drop of NOV03 into each eye.
Study: NCT05162222
Drug: Danicamtiv
Normalized name: Danicamtiv
DrugBank: Danicamtiv (DB18962)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05162222
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05162222
Drug: Diltiazem
Normalized name: Diltiazem
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06035354
Drug: AK120
Normalized name: Abiraterone acetate
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: subcutaneous injection every 2 weeks
Study: NCT06429787
Drug: Balfaxar
Normalized name: Balfaxar
DrugBank: Prothrombin (DB11311)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BALFAXAR (prothrombin complex concentrate, human-lans) is a blood coagulation factor replacement product indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with need for an urgent surgery/invasive procedure
Study: NCT06429787
Drug: Kcentra
Normalized name: Kcentra
DrugBank: Prothrombin (DB11311)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KCENTRA, Prothrombin Complex Concentrate (Human), is a blood coagulation factor replacement product indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with:~* acute major bleeding or~* need for an urgent surgery/invasive procedure
Study: NCT06538285
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine 0.50 mg/kg IM will be administered during the first dosing visit, and either 0.50 mg/kg IM or 0.75 mg/kg IM will be administered at the two subsequent dosing visits, depending on the participant's toleration of prior ketamine dose(s). All ketamine dosing visits will be facilitated by a licensed study therapist and clinician (i.e., NP or MD).
Study: NCT05284409
Drug: Pethidine
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 36 patients will receive 0.5 mg/kg Pethidine IVI
Study: NCT05284409
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 36 patients will receive 0.1 mg/kg Dexamethasone IVI
Study: NCT05362786
Drug: Allogeneic adipose-derived mesenchymal stem cells (MSC)
Normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two intravenous infusions delivered systemically through a peripheral IV(over 30 minutes to 2 hours) of 100x10\^6 cells at day 0 and day 84
Study: NCT05362786
Drug: Allogeneic adipose-derived mesenchymal stem cells (MSC)
Normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous infusion delivered systemically through a peripheral IV(over 30 minutes to 2 hours) of 200x10\^6 cells at day 0
Study: NCT05438394
Drug: melphalan hydrochloride for injection
Normalized name: MELPHALAN HYDROCHLORIDE
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous (iv) infusion for 20 minutes on Day 1 of a 21-day chemotherapy cycle
Study: NCT04781855
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04100694
Drug: MCLA-128
Normalized name: Mcla-128 (igg1 bispecific antibody with enhanced antibody-dependent cell-mediated cytotoxicity (adcc) activity targeting her2 and her3 receptors.)
DrugBank: Zenocutuzumab (DB15559)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05660785
Drug: Herombopag
Normalized name: Hetrombopag
DrugBank: Hetrombopag (DB16184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hetrombopag is a TPO receptor agonist approved in China in 2021 for idiopathic thrombocytopenic purpura (ITP) and second-line severe aplastic anemia (SAA). Indications of chemotherapy-induced thrombocytopenia (CIT), pediatric/juvenile ITP and naive severe aplastic anemia are under development. Hetrombopag was granted Orphan Drug Designation by FDA for the treatment of CIT.~Cyclosporine A is a calcineurin inhibitor, which has an effect on reducing T-cell proliferation and activation, can reverse pancytopenia and alleviate transfusion requirements in NSAA.
Study: NCT05514054
Drug: Imlunestrant
Normalized name: Imlunestrant
DrugBank: Imlunestrant (DB19043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05514054
Drug: Tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered per local approved label.
Study: NCT05514054
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered per local approved label.
Study: NCT05514054
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered per local approved label.
Study: NCT05514054
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered per local approved label.
Study: NCT05005806
Drug: Omega 3 fatty acid
Normalized name: Omega 3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: omega 3 fatty acid soft gel
Study: NCT05750875
Drug: Loratadine
Normalized name: Loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants were given loratadine 10mg, oral, daily, for 4 weeks
Study: NCT05750875
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants were given gabapentin 100mg, oral, daily, for 4 weeks
Study: NCT05790382
Drug: NM-101
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Part 1, each cohort will receive a single dose at one of three dose levels (3 cohorts).~In Part 2, each cohort will receive multiple doses at one of four dose levels (4 cohorts).
Study: NCT02712567
Drug: Th-302
Normalized name: TH-9402 free base
DrugBank: TH-9402 free base (DB17148)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/m2 IV on Days 1 and 8 of a 21-day cycle.
Study: NCT05112536
Drug: Trilaciclib
Normalized name: Trilaciclib
DrugBank: Trilaciclib (DB15442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trilaciclib is administered IV as monotherapy during the lead-in phase and administered prior to chemotherapy on each day chemotherapy is administered during the treatment phase.
Study: NCT05112536
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel administered weekly for the last 12 cycles (cycles 5-16), each cycle 1 week in length.
Study: NCT05112536
Drug: Carboplatin (Investigator discretion)
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin, if given, is administered IV weekly at the start of paclitaxel administration, for the last 12 cycles (cycles 5-16).
Study: NCT04928300
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: low dose dexmedetomidine infusion 0.2 µ/kg/hour IV for 5 days.
Study: NCT04928300
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: low dose ketamine infusion 2.5 µ/kg/min for 5 days.
Study: NCT06072521
Drug: Lactoferrin Bovine
Normalized name: lactoferrin, bovine
DrugBank: Lactoferrin (DB16555)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactoferrin bovine with concentration 100 mg will be given to the patients in test groups in the form of sachets.
Study: NCT05111444
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg on Day 1 of each 3-week cycle as an IV infusion
Study: NCT05111444
Drug: Pyrotinib
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320mg as continuous oral once daily on every 21 days
Study: NCT05111444
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 130 mg/m\^2 on Day 1 of each 3-week cycle over 2 hours as an IV infusion, administered as part of XELOX chemotherapy regimen and as part of SOX chemotherapy regimen
Study: NCT05111444
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 80 mg/m\^2 on Day 1 and Day 8 of each 3-week cycle as an IV infusion, administered as part of FP chemotherapy regimen
Study: NCT05111444
Drug: S-1
Normalized name: LIS-1
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Combination product of tegafur, CDHP, and Oxo. Oral capsules BID on Days 1-14 of each 3-week cycle based on body surface area (BSA): \<1.25 m\^2 BSA =40 mg, 1.25 to \<1.5 m\^2 BSA=50 mg, ≥1.5 m\^2 BSA=60 mg. Administered as part of SOX and TS chemotherapy regimen
Study: NCT04881825
Drug: Glepaglutide
Normalized name: Glepaglutide
DrugBank: Glepaglutide (DB14794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glepaglutide will be delivered in a single-use autoinjector.
Study: NCT06126263
Drug: Linezolid
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive antitoxin therapy